Navigation Links
Anti-cancer drug may treat muscular dystrophy

Recent studies on mice reveal that a drug, being tested as an anticancer agent to treat breast cancer, supports recovery from muscular dystrophy//, a disease that has no cure.

Duchene muscular dystrophy is a disease characterized by progressive weakness and degeneration of the muscles that control movement. According to earlier studies, the functional decline of "dystrophic" muscles can be slowed down by agents that enhance muscle fiber size.

The recent study conducted by Dr. P. L. Puri, from The Burnham Institute in La Jolla, California, and colleagues is published on line yesterday in the journal Nature Medicine. According to this study, the anticancer drug trichostatin A or TSA increases muscles fiber size in two mouse models of muscular dystrophy. Mice with this disability, when given TSA for 3 months, were able to run on treadmills and swim as long as healthy mice. According to the researchers, the drug caused no obvious side effects or signs of toxicity. TSA belongs to a class of drugs called deacetylase inhibitors.

The dystrophic muscles became resistant to contraction-related degeneration when treated with trichostatin A and this is linked with functional and morphological recovery. "We have identified a new rationale for treating muscular dystrophy, aimed at correcting the devastating effects of a single flawed gene," Dr Lorenzo Puri said in a statement. "In the window of time that we have analysed these mice, they seem to perform like normal mice. All the decreases in muscle performance were restored by the treatment. "This is a significant advance over the use of steroid -- currently the only treatment available -- which offers palliative relief, often with severe side effects," he said.

Ms Sharon Hesterlee, a vice-president of the association, which helped finance the research, said "I am hesitant to call the finding a breakthrough, because that could raise expectations unfairly, but it's certainly an i mportant finding."

Puri said, "Extensive investigation is now required to determine if these animal findings also apply to humans with muscular dystrophy. It is difficult to predict how long it will take before these studies will be translated into therapies for human patients," he added. "The next step is to test TSA on larger animals, such as golden retrievers, which contract a form of muscular dystrophy more similar to that in humans, " Dr Puri said.

One in every 3,500 male births is affected by this inherited disease. According to the Muscular Dystrophy Association, 40,000-60,000 people in the US have some form of the inherited disease.
GYT
'"/>




Related medicine news :

1. An Anti-cancer Smart Bomb delivered using a Nanocell
2. Gene Study Offers Hope of Potent Anti-cancer Drugs
3. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
4. Thyroid hormone treatment hastens recovery after cardiac surgery
5. Feeding channel created by malaria parasite - a new target for malaria treatments
6. New drug to treat Heart Attack and damaged tissue
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... 2016 , ... Psoriasis: Targets and Therapy has ... corresponding author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy ... the onset and the severity of psoriasis, and negatively influences the response to ...
(Date:5/31/2016)... ... May 31, 2016 , ... Throughout the day, adults often find themselves reaching for ... awareness, but what they could be reaching for instead is a cup of Matcha green ... grown in Japan. This sacred tea is harvested from early June to mid-July, when the ...
(Date:5/31/2016)... Jose, CA (PRWEB) , ... May 31, 2016 , ... ... , announces its strategic partnership with e-Jan Networks Co., the leading provider of ... enterprises are customers of e-Jan Networks’s leading CACHATTO remote access solution. ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... of advanced Artificial Intelligence (AI) and the latest in Clinical Patient Pod ... is integrating predictive analytic outputs directly into the clinical workflow. These insights are ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... attribute calls back to particular advertising campaigns, to monitor the performance of sales ... they can maximize conversions and revenue. The software allows customers to record, transcribe, ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , May 31, 2016 The ... is progressing at a CAGR of 10.6% within a ... valued at US$0.46 bn in 2013. Owing to favorable ... to reach US$0.88 bn by the end of this ... from the market,s holistic representation in a research report ...
(Date:5/31/2016)... 2016 The global biomaterials market is ... prevalence of deaths from chronic diseases. According to research report, ... Country): Opportunities and Forecasts (2016-2021) - (By Value; By Material ... Surgery, Wound Care); By Region-North America, Europe ... Germany , Italy , ...
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
Breaking Medicine Technology: